1-5 of 5
Dana S. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma

Ian W. Flinn, MD PhD, Thomas J. Ervin, MD, Ralph V. Boccia, MD, Douglas B. Flora, MD, J. Daniel Cuevas, MD, Dana S. Thompson, MD, Dianna L. Shipley, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2015) 126 (23): 1492.
https://doi.org/10.1182/blood.V126.23.1492.1492
Published: 2015
Journal Articles

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, R. Seth Cooper, MD, Dana S. Thompson, MD, Jamie K. Waselenko, MD, James Reeves, Jr., MD, Rudolph L. Wise, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2012) 120 (21): 715.
https://doi.org/10.1182/blood.V120.21.715.715
Published: 2012
Journal Articles

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, Dana S. Thompson, MD, Ralph V. Boccia, MD, Gerald Miletello, MD, Andrew Lipman, MD, Douglas Flora, MD, Daniel Cuevas, MD, Steven W. Papish, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2012) 120 (21): 1624.
https://doi.org/10.1182/blood.V120.21.1624.1624
Published: 2012
Journal Articles

Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

John D. Hainsworth, MD, Dana S. Thompson, MD, F. Anthony Greco, MD, Eric Raefsky, MD, Scott Lunin, MD, James Reeves, Jr., MD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2749.
https://doi.org/10.1182/blood.V120.21.2749.2749
Published: 2012
Journal Articles

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Ian W. Flinn, MD, PhD, Jesus G. Berdeja, MD, Jamie K. Waselenko, MD, R. Seth Cooper, MD, Jia Bi, MD, Kent Shih, MD, Habib H. Doss, MD, Natalie Dickson, MD, Dana S. Thompson, MD, Howard A. Burris, III, MD, John D. Hainsworth, MD
Journal: Blood
Blood (2010) 116 (21): 2461.
https://doi.org/10.1182/blood.V116.21.2461.2461
Published: 2010